BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 79.00 million. The enterprise value is 80.64 million.

Market Cap	79.00M
Enterprise Value	80.64M

Important Dates

The next estimated earnings date is Wednesday, March 19, 2025.

Earnings Date	Mar 19, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.14 billion shares outstanding. The number of shares has increased by 23.34% in one year.

Current Share Class	n/a
Shares Outstanding	2.14B
Shares Change (YoY)	+23.34%
Shares Change (QoQ)	+0.16%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	5.40%
Float	2.03B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.52
PB Ratio	1.40
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.09
EV / Sales	0.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.71

Financial Position

The company has a current ratio of 1.52, with a Debt / Equity ratio of 3.48.

Current Ratio	1.52
Quick Ratio	1.33
Debt / Equity	3.48
Debt / EBITDA	n/a
Debt / FCF	-0.98
Interest Coverage	-7.56

Financial Efficiency

Return on equity (ROE) is -184.09% and return on invested capital (ROIC) is -53.91%.

Return on Equity (ROE)	-184.09%
Return on Assets (ROA)	-32.96%
Return on Capital (ROIC)	-53.91%
Revenue Per Employee	1.03M
Profits Per Employee	-937,230
Employee Count	79
Asset Turnover	0.42
Inventory Turnover	2.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -90.11% in the last 52 weeks. The beta is 1.02, so BioLineRx's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	-90.11%
50-Day Moving Average	6.46
200-Day Moving Average	14.09
Relative Strength Index (RSI)	30.06
Average Volume (20 Days)	18,626,170

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 81.75 million and -74.04 million in losses. Loss per share was -0.06.

Revenue	81.75M
Gross Profit	56.22M
Operating Income	-103.51M
Pretax Income	-74.04M
Net Income	-74.04M
EBITDA	-94.76M
EBIT	-103.51M
Loss Per Share	-0.06

Full Income Statement

Balance Sheet

The company has 108.44 million in cash and 110.08 million in debt, giving a net cash position of -1.64 million or -0.00 per share.

Cash & Cash Equivalents	108.44M
Total Debt	110.08M
Net Cash	-1.64M
Net Cash Per Share	-0.00
Equity (Book Value)	31.62M
Book Value Per Share	0.03
Working Capital	47.90M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -112.53 million and capital expenditures -278,798, giving a free cash flow of -112.81 million.

Operating Cash Flow	-112.53M
Capital Expenditures	-278,798
Free Cash Flow	-112.81M
FCF Per Share	-0.05

Full Cash Flow Statement

Margins

Gross margin is 68.78%, with operating and profit margins of -126.62% and -90.57%.

Gross Margin	68.78%
Operating Margin	-126.62%
Pretax Margin	-90.57%
Profit Margin	-90.57%
EBITDA Margin	-115.92%
EBIT Margin	-126.62%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.34%
Shareholder Yield	-23.34%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -10.48. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.48
Piotroski F-Score	n/a